BRIEF published on 08/27/2024 at 13:05, 1 year 7 months ago Pharnext begins liquidation proceedings Creditors Liquidation Paris Commercial Court Pharnext Suspension Of Listing
BRIEF published on 08/27/2024 at 13:05, 1 year 7 months ago Pharnext entame une procédure de liquidation judiciaire Liquidation Judiciaire Tribunal De Commerce De Paris Suspension De Cotation Pharnext Créditeurs
PRESS RELEASE published on 08/27/2024 at 13:00, 1 year 7 months ago Ouverture d'une procédure de liquidation judiciaire Pharnext SCA, société biopharmaceutique en liquidation judiciaire après procédure de conciliation. Suspension de la cotation des actions Biopharmaceutique Liquidation Judiciaire Suspension Cotation Pharnext Procédure Conciliation
BRIEF published on 07/04/2024 at 20:05, 1 year 9 months ago Pharnext announces the termination of the financing contract granted by Néovacs Investors Termination Funding Pharnext Néovacs
BRIEF published on 07/04/2024 at 20:05, 1 year 9 months ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Financement Investisseurs Pharnext Résiliation Néovacs
PRESS RELEASE published on 07/04/2024 at 20:00, 1 year 9 months ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Pharnext annonce la résiliation anticipée du contrat de financement avec Néovacs suite à des cas de défaut. La société sollicite Global Tech Opportunities 13 pour son soutien Financement Pharnext Résiliation Néovacs Global Tech Opportunities
BRIEF published on 06/18/2024 at 18:35, 1 year 9 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext Procédure De Conciliation CMT1A PXT3003 Tasly
BRIEF published on 06/18/2024 at 18:35, 1 year 9 months ago Pharnext announces the extension of the conciliation procedure until July 15, 2024 Pharnext Conciliation Procedure CMT1A PXT3003 Tasly
PRESS RELEASE published on 06/18/2024 at 18:30, 1 year 9 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 pour poursuivre l'étude clinique de Phase III de PXT3003. Les résultats seront communiqués prochainement Conciliation Étude Clinique Pharnext PXT3003 Maladie Neurodégénérative
BRIEF published on 05/07/2024 at 19:15, 1 year 11 months ago Adjustment of the nominal value at Pharnext Biopharmaceutical Capital Reduction Pharnext Nominal Value Neurodegenerative Diseases
Published on 04/09/2026 at 23:00, 12 minutes ago Apex Critical Metals to Attend Critical Materials Conference: Aerospace & Defence in Washington, DC
Published on 04/09/2026 at 19:15, 3 hours 57 minutes ago Murchison Minerals Announces Adoption of Quarterly Reporting Exemption Under Coordinated Blanket Order 51-933
Published on 04/09/2026 at 16:00, 7 hours 12 minutes ago Banff Half Marathon Completes 2025 Emissions Assessment, Supporting Climate Action with Karbon-X
Published on 04/09/2026 at 14:40, 8 hours 32 minutes ago Silver X Delivers Production Growth During the First Quarter of 2026
Published on 04/09/2026 at 22:00, 1 hour 12 minutes ago Invitation - First Quarter 2026 Trading Update Conference Call
Published on 04/09/2026 at 21:01, 2 hours 11 minutes ago GEVELOT S.A.: PRESS RELEASE CLOSING OF 2025 ACCOUNTS
Published on 04/09/2026 at 21:01, 2 hours 11 minutes ago GEVELOT S.A.: COMMUNIQUE ARRETE DES COMPTES 2025
Published on 04/09/2026 at 20:03, 3 hours 9 minutes ago Annual General Meeting approves all proposals
Published on 04/09/2026 at 18:45, 4 hours 27 minutes ago EUROPLASMA: Tirage de 200 obligations convertibles en actions nouvelles pour un montant nominal de 1M€
Published on 04/09/2026 at 20:00, 3 hours 12 minutes ago SMTPC - Communiqué sur le Chiffre d'affaires du 1er trimestre 2026
Published on 04/09/2026 at 18:35, 4 hours 37 minutes ago Mise à disposition des documents préparatoires à l'Assemblée Générale Mixte du 30 avril 2026
Published on 04/09/2026 at 18:35, 4 hours 37 minutes ago Availability of proxy documents for the Combined General Meeting of April 30, 2026
